@umcutrecht.bsky.social @ox.ac.uk @oxprimarycare.bsky.social #ECRAIDPrime #InfectiousDiseases #ClinicalTrials #PartnerForImpact #EFSM2027
October 30, 2026 at 11:09 AM
At the recent #ESCV2026, Katherine Loens from the Laboratory of Medical Microbiology at @uantwerpen.be presented her team's findings from the #ECRAIDPrime study on the Etiology of Respiratory Infections in Non-hospitalised Patients. @horizoneu.bsky.social @ec.europa.eu @euinemergencies.ec.europa.eu
September 29, 2026 at 7:31 AM
At the recent #ESCV2026, Katherine Loens from the Laboratory of Medical Microbiology at @uantwerpen.be presented her team's findings from the #ECRAIDPrime study on the Etiology of Respiratory Infections in Non-hospitalised Patients. @horizoneu.bsky.social @ec.europa.eu @euinemergencies.ec.europa.eu
🏠 Decentralised trials was a key theme discussed at the #ICTMC2026 last week. Emma Harper and Nicky Maeder from @oxprimarycare.bsky.social presented the #ECRAIDPrime poster to share learnings from the EU-funded #adaptiveplatformtrial in #primarycare.
September 24, 2026 at 8:13 AM
🏠 Decentralised trials was a key theme discussed at the #ICTMC2026 last week. Emma Harper and Nicky Maeder from @oxprimarycare.bsky.social presented the #ECRAIDPrime poster to share learnings from the EU-funded #adaptiveplatformtrial in #primarycare.
#ECRAIDPrime is the only operationally ready #adaptiveplatformtrial of its kind, designed to learn, adapt and evaluate new treatments in general practice and community settings across Europe – and ready to respond rapidly and generate evidence when needed.
August 20, 2026 at 10:55 AM
#ECRAIDPrime is the only operationally ready #adaptiveplatformtrial of its kind, designed to learn, adapt and evaluate new treatments in general practice and community settings across Europe – and ready to respond rapidly and generate evidence when needed.
🙌🏽 Pleased to share that the #ECRAIDPrime LTX-109 study has achieved its recruitment target!
🧪Read more about this EU-funded trial and Phase 2A study on the LTX-109 compound, developed by Pharma Holdings on lnkd.in/eHR28vr9.
🧪Read more about this EU-funded trial and Phase 2A study on the LTX-109 compound, developed by Pharma Holdings on lnkd.in/eHR28vr9.
May 8, 2026 at 8:18 AM
🙌🏽 Pleased to share that the #ECRAIDPrime LTX-109 study has achieved its recruitment target!
🧪Read more about this EU-funded trial and Phase 2A study on the LTX-109 compound, developed by Pharma Holdings on lnkd.in/eHR28vr9.
🧪Read more about this EU-funded trial and Phase 2A study on the LTX-109 compound, developed by Pharma Holdings on lnkd.in/eHR28vr9.
🌟 #Milestone - The #ECRAIDPrime NONS and saline nasal spray study has concluded, marking the completion of a key phase in evaluating treatments for #respiratoryinfections in the community, and proof-of-concept for accelerating clinical research response to outbreaks. 👉🏼
ecraid.eu/news/ecraid-...
ecraid.eu/news/ecraid-...
ECRAID-Prime Reaches Milestone as NONS & Saline Study Concludes | Ecraid
ecraid.eu
April 16, 2026 at 9:33 AM
🌟 #Milestone - The #ECRAIDPrime NONS and saline nasal spray study has concluded, marking the completion of a key phase in evaluating treatments for #respiratoryinfections in the community, and proof-of-concept for accelerating clinical research response to outbreaks. 👉🏼
ecraid.eu/news/ecraid-...
ecraid.eu/news/ecraid-...
A recent article published in Contemporary Clinical Trial Communications evaluates the considerations raised during the regulatory & ethics review of five ID #PlatformTrials: #ECRAIDPrime, #RECLAIM, #REMAPCAP, #RECOVERY, and #SNAP.
Explore the full article here bit.ly/4v0qSCH
#TrialInnovation
Explore the full article here bit.ly/4v0qSCH
#TrialInnovation
Considerations raised during the regulatory and ethics review of platform clinical trials in infectious diseases
Platform trials can address more than one clinical research question simultaneously and allow for the addition or removal of arms over time. The scien…
www.sciencedirect.com
March 31, 2026 at 9:30 AM
A recent article published in Contemporary Clinical Trial Communications evaluates the considerations raised during the regulatory & ethics review of five ID #PlatformTrials: #ECRAIDPrime, #RECLAIM, #REMAPCAP, #RECOVERY, and #SNAP.
Explore the full article here bit.ly/4v0qSCH
#TrialInnovation
Explore the full article here bit.ly/4v0qSCH
#TrialInnovation
What if, in the next infectious disease outbreak, patients are:
🤒 Too sick to travel?
🦠 Unable to visit clinics & traditional research sites?
🏔️ Living in remote or underserved areas?
The #ECRAIDPrime trial demonstrates that research does not need to stop. Trials can come to the patient.
🤒 Too sick to travel?
🦠 Unable to visit clinics & traditional research sites?
🏔️ Living in remote or underserved areas?
The #ECRAIDPrime trial demonstrates that research does not need to stop. Trials can come to the patient.
March 4, 2026 at 9:59 AM
What if, in the next infectious disease outbreak, patients are:
🤒 Too sick to travel?
🦠 Unable to visit clinics & traditional research sites?
🏔️ Living in remote or underserved areas?
The #ECRAIDPrime trial demonstrates that research does not need to stop. Trials can come to the patient.
🤒 Too sick to travel?
🦠 Unable to visit clinics & traditional research sites?
🏔️ Living in remote or underserved areas?
The #ECRAIDPrime trial demonstrates that research does not need to stop. Trials can come to the patient.
🤧 The EU-funded #ECRAIDPrime trial has randomised its first 3 remote patients in the #UK this flu season — launching a patient-centric approach to expand access and community participation. This is a big step for infectious disease trials in #PrimaryCare and #Europe. 🎉 Congrats to the Oxford team!
January 12, 2026 at 2:25 PM
🤧 The EU-funded #ECRAIDPrime trial has randomised its first 3 remote patients in the #UK this flu season — launching a patient-centric approach to expand access and community participation. This is a big step for infectious disease trials in #PrimaryCare and #Europe. 🎉 Congrats to the Oxford team!
The #ECRAIDPrime study is pleased to announce the addition of a third treatment to its ongoing adaptive platform trial in #primarycare and a key component of Europe’s #pandemicpreparedness. Read more on ecraid.eu/news/ecraid-...
April 30, 2025 at 1:09 PM
The #ECRAIDPrime study is pleased to announce the addition of a third treatment to its ongoing adaptive platform trial in #primarycare and a key component of Europe’s #pandemicpreparedness. Read more on ecraid.eu/news/ecraid-...
Respiratory infections like #COVID place a huge strain on healthcare systems worldwide. The EU-funded #ECRAIDPrime study is exploring potential treatments for viral respiratory infections through a first-of-its-kind #adaptiveplatformtrial in primary care. Read more on www.ecraid.eu/news/ecraid-...
ECRAID-Prime Welcomes Georgia: Latest Study Milestones & Updates | Ecraid
The study’s newest country enrols its first patient
www.ecraid.eu
April 2, 2025 at 10:09 AM
Respiratory infections like #COVID place a huge strain on healthcare systems worldwide. The EU-funded #ECRAIDPrime study is exploring potential treatments for viral respiratory infections through a first-of-its-kind #adaptiveplatformtrial in primary care. Read more on www.ecraid.eu/news/ecraid-...